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Abstract
Background: This study protocol describes the Fex-Can Childhood project, comprising two studies: The Fex-Can Childhood
observational study (OS) and the Fex-Can Childhood randomized controlled trial (RCT). The Fex-Can Childhood OS aims to
determine the prevalence and predictors of sexual dysfunction and fertility-related distress in young adult childhood cancer survivors
(aged 19–40) compared to an age matched comparison group; the Fex-Can Childhood RCT will evaluate the effect of a web-based
psycho-educational intervention (Fex-Can intervention) on sexual dysfunction and fertility-related distress.
Methods: The Fex-Can Childhood OS will have a population-based cross-sectional design. All individuals treated for childhood
cancer in Sweden at the age of 0 to 17 years (current age 19–40) will be identified through the National Quality Registry for Childhood
Cancer. Established self-reported instruments will be used to measure sexual function, fertility-related distress, body image, anxiety
and depression, and health-related quality of life. Self-efficacy related to sexual function and fertility, and fertility-related knowledge,
will be assessed by study-specific measures. Clinical variables will be collected from the registry. Results will be compared to an age-
matched comparison group from the general population.
Participants in the Fex-Can ChildhoodOSwho report a high level of sexual dysfunction and/or fertility-related distress will be invited
to participate in the RCT. The Fex-Can intervention comprises two programs: The Fex-Can Sex and the Fex-Can Fertility targeting
sexual dysfunction and fertility-related distress, respectively. The control condition will be a wait-list. Sexual function and fertility-
related distress will be the primary outcomes. The secondary outcomes include body image, anxiety and depression, health-related
quality of life and self-efficacy related to sexual function and fertility. Post- and follow-up assessments will be conducted directly after
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end of intervention (primary end point), at 3 months and 6 months after end of intervention. Additionally, a process-evaluation
including study-specific items and a qualitative interview will be conducted.
Discussion: The Fex-Can Childhood project will advance knowledge in the areas of sexual function and fertility-related distress
among young adult survivors of childhood cancer. If the Fex-Can intervention proves to be efficacious, steps will be taken to
implement it in the follow-up care provided to this population.
Abbreviations: BIS = Body Image Scale, Fex-Can = Fertility and Sexuality following Cancer, Fex-Can Childhood OS = Fex-Can
Childhood Observational Study, Fex-Can Childhood RCT = Fex-Can Childhood Randomized Controlled Trial, GDPR=General Data
protection Regulation, HADS = Hospital Anxiety and Depression Scale, PROMIS = Patient-Reported Outcomes Measurement
Information System, RCAC =Reproductive Concerns After Cancer Scale, RCT= Randomized Controlled Trial, SPAR= the Swedish
Population Register; SexFS = Sexual Function and Satisfaction Measures.
Keywords: childhood cancer, fertility-related distress, intervention, observational study, randomized controlled trial, sexual
function, survivors, young adults
1. Introduction
1.1. Background and rationale
Due to improvements in treatments for childhood cancer in the
recent decades, survival rates have increased dramatically and are
now reaching 80% to 85% in most developed countries. There
are currently about 11,000 survivors of childhood cancer in
Sweden, and a substantial proportion of them are young adults
(19–40 years).[1] The growing number of survivors has led to
increased attention to the late effects of childhood cancer,
including impaired sexual function and infertility. Sexual and
reproductive health are salient issues during young adulthood
and thus strong determinants of the quality of long-term
survivorship.[2]
Among young adult survivors of childhood cancer approxi-
mately half of the women and one third of the men report
problems in one or more areas of sexual functioning.[3–7]
Problems include low sexual interest, impaired ability to get
aroused and low satisfaction with sex life.[8] Survivors of brain
tumors and survivors who received their cancer diagnosis during
adolescence seem to be at particular risk of poor sexual
function.[6,8] Disruptions in normal pubertal development,
premature ovarian failure, and/or the burden of medical late
effects have been suggested as mechanisms involved in these
problems.[4,9,10] Additionally, psychological factors such as
anxiety, depression and negative body image have been
associated to sexual dysfunction following cancer in young
adults.[11,12] Still, due to a paucity of large-scale methodologically
rigid studies, firm knowledge about prevalence rates and the
factors causing sexual problems in survivors of childhood cancer
is lacking.
Cancer therapy can have adverse effects on the reproductive
health in both male and female childhood cancer survivors. The
prevalence of gonadal dysfunction has been reported to be as high
as 66% among males and 11% among female survivors (median
age of 32 years) who were exposed to abdominal/pelvic radiation
and/or to alkylating agents during early childhood.[13,14] Given
the age-related natural decline in follicular reserve, older age at
treatment exposure has also been described as an additional risk
factor for gonadal dysfunction in females.[15] Childhood cancer
survivors thus face reduced fertility compared to their siblings[15–
18] and to the general population.[19,20] Despite the possible threat
of sub-fertility/infertility following treatment for childhood
cancer, many survivors are unaware of their fertility status.[21–
25] Worry about not being able to have a child can be particularly
challenging and lead to distress described as “fertility-related
distress.”[26] Health of the future biological children, own health
in the future, and pregnancy-induced cancer recurrence are
seemingly major concerns for survivors.[23,27–29] However, both
qualitative and population-based studies report that survivors’
perception of own fertility status are not aligned with their actual
fertility status.[30–32] It is therefore likely that misperceptions
about fertility lead to unnecessary and inappropriate worry
regarding fertility.[33] Moreover, population-based studies with
accurate estimates of the prevalence of fertility-related distress in
childhood cancer survivorship are lacking.
In order to advance, this field of knowledge, there is a need to
establish prevalence rates of sexual dysfunction and of fertility-
related distress in young adults treated for cancer during their
childhood. To reach such aim, large-scale and methodologically
rigorous studies investigating these issues in bothmale and female
survivors are needed. Also, reliable comparisons with the general
population and investigations of the association between these
issues and different cancer types, treatment intensity, and age at
diagnosis should be made. Furthermore, even though sexual
problems and fertility-related distress have been reported among
young adult survivors of childhood cancer in numerous previous
studies, there is a lack of specific interventions targeting these
issues. Web-based or e-Health interventions have been estab-
lished to be efficacious in terms of improvement of quality of life
in a variety of somatic populations.[34–37] There are a few studies
that have focused on the effectiveness of web-based interventions
to overcome sexual and reproductive problems following cancer.
One such intervention showed improved social and physical
functioning and fertility-related knowledge in young adults in the
aftermath of cancer.[38] Another intervention aimed to decrease
sexual problems in female breast cancer survivors and also
demonstrated positive effects over time.[39] Still, to date, no web-
based intervention with the aim to reduce sexual problems and
fertility-related distress has been developed and tested in young
adult survivors of childhood cancer.
With the above concerns in consideration the project Fertility
and Sexuality following Cancer (Fex-Can) was launched. The
overall aim of the Fex-Can project is to improve sexual and
reproductive health in young adults who have been treated for
cancer. Within this project, a web-based intervention (Fex-Can
intervention) has been developed in close cooperation with young
adults with a cancer experience.[40] The Fex-Can intervention is a
web-based psychoeducational intervention consisting of two
programs; the Fex-Can Sex and the Fex-Can Fertility, targeting
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sexual dysfunction and fertility-related distress, respectively. The
Fex-Can intervention has been evaluated as to its feasibility with
satisfactory results.[41] Besides the Fex-Can Childhood project
described in this protocol, a sister project focusing on sexual
problems and fertility-related distress in young adults recently
diagnosed with cancer is currently running, as described in two
separate protocols.[42,43]
The Fex-Can Childhood project targets young adult survivors
of childhood cancer (cancer diagnosis at the age of 0–17 and
currently aged 19–40) and consists of two studies:
1. A population-based observational study determining sexual
dysfunction and fertility-related distress in this population; the
Fex-Can Childhood observational study (Fex-Can Childhood
OS), and
2. A randomized controlled trial (RCT) evaluating the Fex-Can
intervention; the Fex-Can Childhood RCT.
The present protocol describes the whole Fex-Can Childhood
project including both the Fex-Can Childhood OS and the Fex-
Can Childhood RCT.
1.2. Objectives
The aim of the Fex-Can Childhood OS is to determine the
prevalence and predictors of sexual dysfunction and fertility-
related distress in young adult childhood cancer survivors (aged
19–40) compared to an age matched comparison group. The
aim of the Fex-Can Childhood RCT is to evaluate whether the
Fex-Can intervention is effective in terms of reduction of sexual
dysfunction and fertility-related distress in young adult
survivors of childhood cancer. An additional aim of the Fex-
Can Childhood RCT is to test the effect of the Fex-Can
intervention on the secondary outcomes, that is, health-related
quality of life, symptoms of anxiety and depression, body
image, fertility knowledge, and self-efficacy related to sexuality
and fertility.
2. Methods
2.1. Design
The Fex-Can Childhood project started January 2019 and is
expected to run till November 2020. The Fex-Can Childhood OS
will have a population-based cross-sectional design, including an
age matched comparison group. The Fex-Can Childhood RCT
will test the effect of the Fex-Can intervention by using an RCT
with a superiority design and a 1:1 allocation ratio. The active
group will receive the Fex-Can intervention for 12 weeks (either
the Fex-Can Sex or the Fex-Can Fertility version of the program)
and the control group will be on a wait-list. The effect of the Fex-
Can intervention will be evaluated directly after end of the
program (primary endpoint), and at 3-month follow-up. The
control group will receive access to the intervention after the 3-
month follow-up assessment. An additional follow-up assess-
ment will be conducted at 6 months after end of the program
which will be used to analyze sustainment of a potential effect for
the intervention group. To achieve a deeper understanding of the
participants’, use of the intervention, and of the role of the
program in bringing about a possible change in the selected
outcomes, a process-evaluation including survey questions and
qualitative interviews will also be conducted. See Figure 1 for
flow diagram of the Fex-Can Childhood RCT.
2.2. Study setting and recruitment
2.2.1. Fex-Can Childhood OS.
 Cancer survivor group
Participants will be identified using the National Quality
Registry for Childhood Cancer which is a quality registry of all
children diagnosed with cancer or brain tumors who are treated
at pediatric oncology centers in Sweden.[44] At present, the
registry includes ∼4500 survivors of childhood cancer in the age-
span 19 to 40 years. A letter with study information will be sent to
all individuals in the registry matching the inclusion criteria (see
below), emphasizing that participation is voluntary and that non-
participation will not affect potential care. On acceptance to
participate, self-administered questionnaires will be collected by
paper or web. Two reminders will be sent to non-responders.
Participants will be rewarded with two cinema tickets for
participating in the study.
 Comparison group
A comparison group consisting of a random sample of 2000
individuals (1000 women and 1000 men) drawn from the
Swedish population register (SPAR) have been approached
regarding study participation. The self-administered question-
naires (same as for the cancer group besides cancer specific items
which were edited out), together with a letter with information
about the study, including the voluntary nature of participation,
was sent to potential participants. As for the cancer group, it was
optional to complete the survey via paper or web, and two
reminders were sent to non-responders. The comparison group
was offered the same compensation for participation as the
cancer group, that is, two cinema tickets. The comparison group
data was collected during 2018.
2.2.2. Fex-Can Childhood RCT. Participants in the Fex-Can
Childhood OS study (cancer survivor group) who report sexual
dysfunction or fertility-related distress will be invited to
participate in the Fex-Can Childhood RCT (see criteria below).
Invitation will be sent via post and individuals who accept
participation will be allocated to either the Fex-Can Sex or Fex-
Can Fertility program according to the primary issues reported by
them, that is, the Fex-Can Sex for those reporting high levels of
sexual dysfunction and Fex-Can fertility for those reporting high
levels of fertility-related concerns.
The assessment in the Fex-Can Childhood OS will be used as
baseline assessment in the Fex-Can Childhood RCT. Post- and
follow-up assessments will be collected directly after end of
intervention, at 3 months after end of intervention (short-term
follow-up), and at 6 months after end of the intervention (long-
term follow-up). Participants in the wait-list control group will
receive the intervention after completion of the short-term follow-
up assessment. Directly after the intervention they will also
complete the post-intervention assessment.
2.3. Eligibility criteria
2.3.1. Inclusion criteria Fex-Can Childhood OS.
 Cancer survivor group
1. Individuals diagnosed with malignant disease at the age of 0 to
17 years and registered in the National Quality Registry for
Childhood Cancer.
2. Age 19 to 40 at the time of enrollment and registered as
residents in Sweden.
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 Comparison group
1. Age 19 to 40 at the time of enrollment (matching the age of the
cancer group) and registered as residents in Sweden.
2.3.2. Inclusion criteria Fex-Can Childhood RCT. Participat-
ing in the Fex-Can Childhood OS study (cancer survivor group)
and reporting a high level of sexual dysfunction and/or fertility-
related distress. In order to be eligible to be enrolled into the Fex-
Can Sex program participants should report sexual dysfunction
(defined as 0.5 SD from the population mean) in at least one of the
selected domains (for specification of domains, see below under
Primary outcomes) of the Patient-Reported Outcomes Measure-
ment Information System Sexual Function and Satisfaction
measure version 2.0 (SexFS version 2.0), or report not having
had sex due to cancer-related reasons.[45] To be eligible to be
enrolled in the Fex-Can Fertility program, individuals should
report fertility distress (defined as a mean score>4) in at least one
dimension of theReproductiveConcernsAfter Cancer (RCAC)[46]
(for further description of these assessments, see Section 4.3.3).
2.3.3. Exclusion criteria Fex-Can Childhood OS/RCT.
1. Individuals who are unable to read/write in the Swedish
language.
Figure 1. Consort-flow chart for the Fex-Can Childhood RCT
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2. Individuals who report poor health and/or substantial
cognitive impairment that prevent completion of the survey
and/or participation in the intervention.
2.4. Intervention
The Fex-Can Intervention is a web-based self-help intervention
that comprises two programs: The Fex-Can Sex and the Fex-Can
Fertility targeting sexual dysfunction and fertility-related distress,
respectively. The intervention has originally been developed
together with young adult survivors of cancer as research
partners (described in detail elsewhere using a co-creative long-
term collaboration).[40] The feasibility assessment of the
intervention has provided satisfying results, rendering it suitable
for young persons with cancer in terms of demand, acceptability,
preliminary efficacy, and functionality.[8] Both the Fex-Can Sex
and the Fex-Can Fertility programs are structured in six modules
which will be delivered over a period of 12 consecutive weeks. A
detailed description of the modules and their content has been
presented elsewhere.[41] Briefly, the modules comprise educa-
tional and behavior modification content, exercises, illustrations
and quizzes. For the Fex-Can Childhood RCT, all contents of the
modules have been adapted to be suitable for participants
previously diagnosed with childhood cancer with respect to the
age of diagnosis (0–17 years), various types of childhood cancer
diagnoses and common treatment modalities. The program has
been created bearing in mind the likelihood that some of the
participants may not remember having experienced cancer and its
treatment. Great care has also been taken to develop the
intervention to fit participants irrespective of sexual orientation,
if they have a partner or not, and if they have or have not had sex.
Additionally, the modules include video vignettes of young adult
survivors of childhood cancer describing their experiences
regarding the topics covered. The aim of the exercises is to
increase sexual pleasure and function (Fex-Can Sex), and
counteract worries related to threatened or lost fertility and on
managing parenthood (Fex-Can Fertility). The intervention also
includes an online-moderated discussion forum, that is, join
between the two programs. The intervention will be delivered on
a platform with a responsive design suitable to be used on
computers, tablets, and smartphones.
2.4.1. Compliance. In order to achieve a high compliance to the
intervention, participants will receive text/e-mail notifications at
the opening of each of the six modules. Compliance will be
evaluated through the log function in the web platform that
records the log-in information of all participants and also their
usage of different program functions. Furthermore, the post-
intervention assessment (directly after end of program) will
include questions about the participants’ use of different program
features.
2.4.2. Concomitant care. Concomitant care and treatment for
sexual dysfunction and/or fertility-related distress will not be
Table 1
Timeline for Fex-Can Childhood OS/RCT.
Baseline
assessment
(OS/RCT)
Post-intervention
assessment (RCT)
Short-term follow-up
assessment (RCT)
Long-term follow-up
assessment (RCT)
Survey data Measures
Primary outcomes
Sexual function SexFS version 2.0 x x x x
Fertility-related distress RCAC x x x x
Secondary outcomes
Body image BIS x x x x
Anxiety and depression HADS x x x x
Health-related quality of life EORTC QLQ-C30 x x x x
Self-efficacy sexual function Study-specific items x x
∗
x
∗
x
∗
Self-efficacy fertility Study-specific items x x† x† x†
Fertility-related knowledge Study-specific items x x† x† x†
Additional survey data
Socio-demography Study-specific items x
Use of prescription drugs Study-specific questionnaire‡ x
Process evaluation Study-specific items x
Clinical data
Cancer diagnosis National quality registry x
Clinical tumor stage National quality registry x
Treatment type and intensity National quality registry x
Classified according to ITR
Recurrence National quality registry x
Interview data
Process evaluation Semi-structured interview x
BIS=Body Image Scale; EORTC QLQ-C30=European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire-C30 version 3.0; HADS=Hospital Anxiety and Depression Scale;
ITR= Intensity of Treatment Rating scale 3.0; RCAC=Reproductive Concerns after Cancer scale; SexFS=Sexual Function and Satisfaction Measure version 2.
∗
Self-efficacy sex is completed by participants in the Fex-Can Sexuality program.
† Self-efficacy fertility and fertility-related knowledge is completed by participants in the Fex-Can Fertility program.
‡ Based on the Childhood Cancer Survivor Study questionnaire.
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inhibited by study participation. Information about the use of
such care will be collected in the post- and follow-up assessments.
2.5. Measurements
All standardized measures will be used and analyzed in line with
the guidelines provided in their respective manuals. The
questionnaire battery has been tested in two groups of young
women and men with cancer and showed high acceptance
level.[47,48] See Table 1 for a presentation of the administration of
instruments.
2.6. Primary outcomes
2.6.1. Fex-Can Childhood OS/RCT
 Sexual function
Sexual function will be assessed using the SexFS version 2.0.
The SexFS version 2.0 is a self-rated measurement that consists of
a set of domains that represents different areas of sexual function
and satisfaction. For the present study the following domains will
be selected for women: Vaginal lubrication, Vaginal discomfort,
Vulvar discomfort—clitoral, and Vulvar discomfort—labial. For
males, the domain Erectile function will be selected. Additionally,
four gender-neutral domains will be included for all participants:
Interest in sexual activity, Orgasm—ability, Orgasm—pleasure,
and Satisfaction with sex life. For most items responses in the
SexFS version 2.0 are given with five options from, for example,
“never” to “always.” Item responses in each domain are used to
calculate domain scores which are transformed to a T-score
metric where 50 represents the mean for the American general
population (standard deviation = 10).[45] In addition to the
domains, items assessing bother related to sexual function and
screener items assessing sexual activity will be included.
The SexFS has shown adequate content, construct and known-
groups validity as well as test-retest reliability.[45,49] The selected
items and domains of the SexFS version 2.0 have been translated
into Swedish and linguistically validated in accordance with the
procedure developed by FACITrans and PROMIS.[50]
 Fertility-related distress
Fertility-related distress will be assessed using the RCAC. The
RCAC is a self-rated multidimensional scale, measuring a range
of fertility and parenthood concerns, originally developed and
evaluated for young adult female cancer survivors (age 18–35
years).[46] There are 18 items in the scale, the responses for which
are scored on a five-point scale (ranging from 1 = strongly
disagree to 5 = strongly agree). The RCAC includes six
dimensions: Fertility potential, Partner disclosure, Child’s health,
Personal health, Acceptance, and Becoming pregnant/Achieving
pregnancy (each dimension consists of three items). In each
dimension, a high level of reproductive concerns is defined as a
mean score ≥4. The RCAC has demonstrated satisfactory
internal consistency and construct validity.[46,51,52] The scale has
independently been translated into Swedish by two bilingual
researchers, and has been evaluated by one bilingual panel (n=4),
one lay panel (n=7), and one patient panel (n=8), as well as by
cognitive interviews with 3 young patients with cancer before the
launch of the Fex-Can project.
2.6.2. Fex-Can Childhood RCT. The primary outcome in the
Fex-Can Sex program will be the total score (continuous
measure) in the domain ‘Satisfaction with sex life’ whereas the
overall mean score of the RCAC will be used to evaluate effect of
the Fex-Can Fertility program.
2.7. Secondary outcomes
2.7.1. Fex-Can Childhood OS/RCT. The secondary outcomes
will be fertility-related knowledge (the Fex-Can Fertility); body
image; health-related quality of life; symptoms of anxiety and
depression; and self-efficacy related to sexuality and fertility (the
Fex-Can Sex and the Fex-Can Fertility, respectively). In addition,
secondary outcomes will include all the domains of the SexFS
version 2.0 besides “Satisfaction with sex life” (used as primary
outcome), the items assessing bother related to sexual function,
and screener items assessing sexual activity. Also, the specific
dimensions of RCAC will be used as secondary outcomes.
 Fertility-related knowledge
A study-specific questionnaire will be used to assess fertility-
related knowledge. The questionnaire includes 10 items
measuring perceived level of knowledge about general and
cancer-related fertility issues. For males, there are totally 9 items
with the exception of one item regarding the effect of the cancer/
cancer treatment on pregnancy and child birth. Responses are
provided on a four-point scale ranging from 1=disagree
completely to 4 = agree completely. Examples of items are: “I
have good knowledge regarding the effect of age on the
reproductive ability” and “I have good knowledge regarding
the effect of cancer and cancer treatments on pregnancy and
delivery.” Total mean scores will be calculated with higher scores
indicating higher levels of perceived fertility-related knowledge.
 Body image
The Body Image Scale (BIS) will be used to assess body image
discomfort associated with cancer and cancer treatment.[53] The
BIS contains 10 items which are scored from 0 to 3 with higher
scores indicating a more negative body image. The BIS has shown
high test–retest reliability and good internal consistency in cancer
patients.[53]
 Health-related quality of life
The QLQ-C30 (version 3.0), developed by the European
Organization for Research and Treatment of Cancer (EORTC),
will be used to assess health related quality of life. The QLQ-C30
(version 3.0), is a 30-item questionnaire developed to assess the
general aspects of quality of life and common symptoms specific
to cancer patients.[54,55] It includes five functional scales
(physical, role, emotional, cognitive, and social), three symptom
scales (fatigue, nausea/vomiting, and pain), a global health status
scale, and six single items (dyspnea, insomnia, appetite loss,
constipation, diarrhea, and financial impact). The questionnaire
has exhibited good psychometric properties in cancer popula-
tions.[13,15] The summary score for the QLQ-30 will be used
according to the EORTC QLQ-C30 Scoring Manual (3rd
Edition) (2001).[55]
 Anxiety and depression
The Hospital Anxiety and Depression scale (HADS) will be
used to assess anxiety and depression.[56] The HADS encom-
passes two subscales with 7 items each, measuring symptoms of
anxiety and depression, respectively. Both subscales have shown
satisfactory internal consistency and good to very good
concurrent validity.[57]
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 Self-efficacy
Self-efficacy will be evaluated using a study-specific question-
naire assessing the participant’s confidence in one’s own ability to
handle situations, thoughts and emotions related to the threat of
infertility (6 items) and sexuality (6 items). For example, “I feel
confident that I have a positive attitude about my sex life” (Fex-
Can Sex) and “I feel confident that I can deal with meeting friends
or relatives expecting a child” (Fex-Can Childhood Fertility).
Total mean scores will be with higher scores indicating higher
levels of self-efficacy related to sexuality and fertility, respectively.
2.8. Additional survey data
In the survey, questions regarding socio-demographics will also
be included. Additionally, the use of prescription drugs over the
last 2 years will be assessed by use of a study-specific
questionnaire. It is a shortened version of a comprehensive
survey developed for use in survivors of childhood acute myeloid
leukemia in the Nordic countries[58,59] originally inspired by the
Childhood Cancer Survivor Study questionnaire.[60] The items in
the questionnaire were adapted for assessment of prescription
drug usage in childhood cancer survivors included in the Fex-Can
Childhood project.
2.9. Administration of instruments
The instruments will be administered in the following order at all
assessments: BIS; RCAC; Self-efficacy Fertility; Fertility-related
knowledge; Self-efficacy Sexuality; SexFS version 2.0; HADS;
EORTC QLQ-30 version 3.0; and use of prescription drugs.
2.10. Clinical data
2.10.1. Fex-Can Childhood OS/RCT. Following formal con-
sent from the National Quality Registry for Childhood Cancer,
clinical data will be obtained. The data will include cancer
diagnosis and clinical stage, date of diagnosis, treatment type and
intensity, and recurrence or new cancer diagnosis after treatment.
Treatment intensity will be categorized in accordance with the
Intensity of Treatment Rating scale (ITR-3.0).[61] Clinical
variables will be selected in close collaboration with a clinician
(KJ) with vast expertise in pediatric oncology and a representative
from the National Quality Registry for Childhood Cancer in
Sweden.
2.11. Process evaluation
2.11.1. Fex-Can Childhood RCT
 Post-intervention survey
In addition to the primary and secondary outcomes, the post-
intervention survey will include questions regarding adherence to
the program, use of the different features of the program, and
perception of change in sexual problems and/or fertility-related
distress. These questions will be administered to the participants
belonging to the intervention group andwill encompass 13 study-
specific items. Participants will also be requested to comment on
the content and features of the intervention. Responses will be
provided on a four-point scale ranging from “Disagree
completely” to “Agree completely.” Additionally, participants
will be requested to score their present levels of problems
(concerning sex life or fertility-related distress) in comparison to
the level before they entered the Fex-Can Childhood intervention.
Responses will be given on a 7-point scale, ranging from “Much
improved” to “Much worsened” with the midpoint “No
change.”
2.11.2. Semi-structured interview. Semi-structured interviews
will be conducted with a purposive sample of ∼30 participants in
the intervention group in order to achieve a deeper understanding
of the intervention usage, and the role of the program in bringing
about a change in the outcomes. The interviews will be performed
via telephone, shortly after completion of the intervention.
Questions will explore the participants’ view of their sexual
problems or fertility-related distress and if/how these problems
have changed during the course of the intervention. Participants
will also be asked to describe their experiences of participating in
the intervention and their use of the different program functions.
The interviews will be digitally recorded, transcribed verbatim
and will be analyzed using qualitative content analysis.[62]
2.12. Participant timeline
See Table 1 for study timeline.
2.13. Sample size
All eligible individuals registered in the National Quality Registry
for Childhood Cancer and matching the inclusion criteria for the
Fex-Can Childhood OS-study (∼4500) will be approached and
invited to participate.With an estimated response rate of 60% the
sample size (n=2700) will be large enough to analyze clinical and
sociodemographic predictors of the sexual dysfunction and
fertility-related distress. With regards to the Fex-Can RCT we
expect ∼50% of the participants in the Fex-Can OS study to rate
high levels of sexual problems or fertility-related distress (n=
1350). These individuals will be invited to participate in the RCT.
In order to detect a statistically significant group difference with a
power of 80%, estimatingmedium effect size (0.5) and a=0.05, a
total of 128 completers (post-intervention assessment) will be
required in each version of the program in the RCT. We expect
∼30% of the individuals who are invited to the RCT to agree to
participate (n=405). With an estimated attrition rate of 15% at
the post-intervention assessment we will reach well over 256
completers and achieve adequate statistical power in the Fex-Can
RCT.
2.14. Randomization
Participants will be randomly assigned to either intervention-
group or wait-list control-group with an allocation ratio of 1:1.
Participants will be allocated in blocks stratified by sex and
diagnosis (leukemia/lymphoma; brain tumor; solid tumor). The
randomization will be carried out separately for the two
programs of the RCT (Fex-Can Childhood Sex and Fex-Can
Childhood Fertility). In the event that participants’ eligibility
criteria are met for both programs, an evaluation of individual
scores will be performed based on severity of reported problems
by a registered psychologist and a registered nurse specialized in
psychosocial oncology.
In order to minimize bias, the computer-generated randomi-
zation sequence will be created by a statistician not directly
involved in the management of the trial and the information
regarding the series of random numbers will be kept unknown to
the investigators.
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2.15. Blinding
Due to the nature of the intervention, it is not possible to conceal
the participants’ group allocation to the researchers involved in
providing and monitoring the intervention and data collection.
Hence, full blinding is infeasible during the intervention in the
present study, however, participants’ allocation to intervention
or control groups will be masked in the data set available for
researchers during data analysis.
2.16. Statistical methods
2.16.1. Fex-Can Childhood OS. All data analyses will be
performed and reported in accordance with STROBE[63] for
observational studies. With the exception of descriptive statistics
and visualizations, multiple regression models will be the main
class of statistical method used to analyze prevalence and
predictors of the outcomes. Missing data will be investigated
using descriptive statistics and significance testing.
2.16.2. Fex-Can Childhood RCT. All data analyses will be
performed and reported in line with the SPIRIT-PRO Extension
for randomized clinical trials.[64] The statistical analyses will
primarily aim at comparing the intervention with the control
group directly after end of program. The 3-month follow-up
assessment will be used as secondary end-point comparing the
intervention group and the control group. In addition, sustain-
ment of a potential effect for the intervention group at 6 months
(long-term assessment) will be evaluated. Missing data will be
investigated using descriptive statistics and significance testing.
Intention-to-treat analyses will be applied for the primary
outcomes in the RCT.
All statistical analyses will be conducted by external
statisticians, who are not aware of the study participants’ group
allocation. SPSS Statistics version 26 (IBM Corp., Armonk, NY)
will be used for data management and statistical analyses.
2.17. Adverse effects
In order to assess adverse effects for participants in the Fex-Can
Childhood RCT, the number of participants reporting possible
worsening of symptoms in the primary or secondary outcomes
will be evaluated. Furthermore, participants will be asked to
specify in the post-intervention survey if they have experienced
any worsening of symptoms. Additionally, during the semi-
structured post-intervention interview, participants will be asked
to describe possible adverse effects experienced.
2.18. Ethics and dissemination
2.18.1. Research ethics approval. Ethical approval has been
granted by the Regional Ethical Review Board in Stockholm,
Sweden (Dnr: 2015/1609-31; 2018/2688-32; 2019/01066; 2019/
04603).
2.18.2. Confidentiality. A unique code number will be assigned
to all participants and indicated on the survey. The code key will
be maintained separately from the research data and will only be
accessible by members of the research team. Participants will
access the web portal by using an alias of their own choice. The
researchers will be able to connect participants’ alias to the code
number only at the stage of analyzing data. All data will be
handled and stored in accordance to the EU General Data
Protection Regulation (GDPR).
2.18.3. Dissemination policy. The results from the trial will be
communicated to the scientific, clinical and patient communities
through publications in scientific peer-reviewed open-access
journals and presentations at international clinical and scientific
conferences and in other contexts.
3. Discussion
Several studies of childhood cancer survivors demonstrate
impairment in sexual and reproductive functions.[15,65,66] This
include different types of sexual dysfunctions, negative impact on
intimate relations, and the emotional consequences of living with
threatened or actual infertility. There is, however, a lack of large-
scale methodologically rigid studies on the prevalence of these
issues, and of the factors associated to them. Furthermore, there
are no studies evaluating interventions to decrease sexual
problems and fertility-related distress in adult survivors of
childhood cancer. The Fex-Can Childhood project includes two
studies aiming to fill these gaps in the previous literature. The
observational study, the Fex-Can Childhood OS, will determine
occurrence and predictors of sexual problems and fertility-related
distress. Fex-Can Childhood RCT on the other handwill evaluate
the effect of a web-based self-help intervention that aims to
alleviate these issues among childhood cancer survivors.
There are several strengths of the design of the studies in this
project. First, the Fex-Can Childhood OS will have a population-
based inclusion procedure using the National Quality Registry
for Childhood Cancer, which allows for identification of the
whole population of young adult childhood cancer survivors in
Sweden. Also, the use of clinical data from the registry will
provide high quality clinical variables consolidated from the
various registries for childhood cancer diagnosis.[44,67] Further-
more, a strength of the study is the collection of comparison data
from the general population of the same age using the same
outcome measurements. This will provide reliable comparison
data and thus, reliable estimates of prevalence in the target
population. Lastly, strength of the study is the use of established
instruments that have undergone psychometric testing instru-
ments of sexual function and fertility-related distress, as well as of
secondary outcomes.
With regards to the Fex-Can Childhood RCT, a main strength
is the RCT-design which is the gold standard in clinical research.
Another major strength is the two parallel-arm-designs, which
will allow evaluation of both versions of the intervention; the
Fex-Can Sex (targeting sexual problems) and the Fex-Can
Fertility (targeting fertility-related distress). In addition, the
assessment of several secondary outcomes will investigate
additional effects of the intervention as well as potential
interactions with other processes related to the outcomes, which
will enhance the clinical relevance of conclusions. Lastly, by
providing the intervention to the wait-list control group after end
of the short-term follow-up assessment, all participants will be
offered the intervention which may increase motivation to
participate in the trial, and thus minimize selection bias.
Some potential limitations of the project should also be
mentioned. For the Fex-Can Childhood RCT a potential
limitation is the lack of certainty with regards to prevalence
rates of sexual problems and fertility-related distress in this
population since these are key determinants of inclusion rate.
Prevalence rates will impact the number of participants that can
be invited to participate in the RCT, and the number that will be
included, and thus will affect the possibility to reach adequate
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statistical power in the study. In addition, the cut-off values
selected for inclusion have not been evaluated previously and the
clinical relevance of sexual problems and fertility-related distress
at levels above these cut-offs are yet to be determined.
In conclusion, the present study protocol describes a popula-
tion-based observational study investigating sexual problems and
fertility-related distress in young adult childhood cancer
survivors and the clinical trial of the Fex-Can intervention; the
first web-based intervention targeting sexual problems and
fertility-related distress in this population. The results from these
studies will have significant clinical implications by both
determining the prevalence of sexual problems and fertility-
related distress in the aftermath of childhood cancer, and by the
potential to provide an effective intervention aiming to alleviate
these issues. In the event that the Fex-Can intervention proves to
be efficacious, steps will be taken to implement it in routine care
for young adult childhood cancer survivors. Together these two
studies that constitute the Fex-Can Childhood project, will
advance knowledge in the area and has the potential to improve
care provided to childhood cancer survivors in the future.
See Appendix: http://links.lww.com/MD/E109.
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